Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

- 1. (currently amended) A <u>synthetic</u> peptide factor comprising amino acid residues 33 to 42 of murine epidermal growth factor <u>having the sequence of SEQ ID NO:2 peptide</u> wherein:
- a) the peptide factor said sequence is modified such that at least one or both of i) SEQ ID NO:2 murine epidermal growth factor tyrosine amino acid residue 5 is substituted with a tyrosine analogue or at least one and ii) murine epidermal growth factor SEQ ID NO:2 arginine amino acid residue 9 is are substituted with an a tyrosine analogue or arginine analogue, respectively; and
 - b) the synthetic peptide factor binds is capable of binding to laminin receptors.
- 2. (currently amended) The <u>synthetic</u> peptide factor of claim 1, <u>having an N-terminal amino</u> <u>acid residue and a C-terminal amino acid residue</u>, wherein the N-terminal <u>amino acid residue</u> of the murine epidermal growth factor <u>amino acid residue</u> is chemically modified by the addition of an amino acid capping moiety, the C-terminal <u>amino acid residue</u> of the murine epidermal growth factor <u>amino acid residue</u> is chemically modified by the addition of an amino acid capping moiety, or a murine epidermal growth factor cysteine residue thiol group is chemically modified by the addition of an amino acid capping moiety to the cysteine residue thiol group.
- 3. (currently amended) The <u>synthetic</u> peptide factor of claim 1, wherein the murine epidermal growth factor <u>SEQ ID NO:2</u> tyrosine residue <u>5</u> is substituted by tetrahydroisoquinoline-3-carboxylic acid.
- 4. (currently amended) The <u>synthetic</u> peptide factor of claim 1, wherein the <u>murine</u> epidermal growth factor <u>SEQ ID NO:2</u> arginine residue <u>9</u> is substituted by Citrulline.

PHIP\390518\1 - 2 -

- 5. (currently amended) A method of antagonizing a laminin receptor in a patient, the method comprising the steps of:
- a) administering to the patient a medicament comprising a <u>synthetic</u> peptide factor comprising amino acid residues 33 to 42 of murine epidermal growth factor <u>having the sequence</u> of SEQ ID NO:2 wherein the peptide factor <u>said sequence</u> is modified such that at least one <u>or both of i) SEQ ID NO:2</u> murine epidermal growth factor tyrosine amino acid residue <u>5</u> is substituted with a tyrosine analogue or at least one <u>and ii) SEQ ID NO:2</u> murine epidermal growth factor arginine amino acid residue <u>9</u> is <u>are</u> substituted with <u>an a tyrosine analogue or arginine analogue, respectively, and</u>
 - b) binding the synthetic peptide factor to the laminin receptor.
- 6. (currently amended) A method of agonizing a laminin receptor in a patient, the method comprising the steps of:
- a) administering to the patient a medicament comprising a <u>synthetic</u> peptide factor comprising amino acid residues 33 to 42 of murine epidermal growth factor <u>having the sequence</u> of <u>SEQ ID NO:2</u> wherein the peptide factor <u>said sequence</u> is modified such that at least one <u>or both of i) SEQ ID NO:2</u> murine epidermal growth factor tyrosine amino acid residue <u>5</u> is <u>substituted with a tyrosine analogue or at least one murine epidermal growth factor and ii) SEQ ID NO:2</u> arginine amino acid residue <u>9</u> is <u>are</u> substituted with <u>an a tyrosine analogue or</u> arginine analogue, respectively, and
 - b) binding the synthetic peptide factor to the laminin receptor.
- 7. (previously presented) The method of claim 6 wherein said medicament is for treating endothelial cell wounding.
- 8. (previously presented) The method according to claim 6 wherein said medicament is for treating retinopathy of prematurity.
- 9. (currently amended) The <u>synthetic</u> peptide factor of claim 2, wherein the murine epidermal growth factor <u>SEQ ID NO:2</u> tyrosine residue <u>5</u> is substituted by tetrahydroisoquinoline-3-carboxylic acid.

PHIP\390518\1 - 3 -

10. (currently amended) The <u>synthetic</u> peptide factor of claim 2, wherein the murine epidermal growth factor <u>SEQ ID NO:2</u> arginine residue <u>9</u> is substituted by Citrulline.

11. (canceled)

- 12. (currently amended) The method of claim 5, wherein said synthetic peptide has an N-terminal amino acid residue and a C-terminal amino acid residue, wherein the N-terminal amino acid residue of the murine epidermal growth factor amino acid residue is chemically modified by the addition of an amino acid capping moiety, the C-terminal amino acid residue of the murine epidermal growth factor amino-acid residue is chemically modified by the addition of an amino acid capping moiety, or a murine epidermal growth factor cysteine residue thiol group is chemically modified by the addition of an amino acid capping moiety to the cysteine residue thiol group.
- 13. (currently amended) The method of claim 12, wherein the murine epidermal growth factor SEQ ID NO:2 tyrosine residue 5 is substituted by tetrahydroisoquinoline-3-carboxylic acid.
- 14. (currently amended) The method of claim 12 wherein the murine epidermal growth factor SEQ ID NO:2 arginine residue 9 is substituted by Citrulline.
- 15. (currently amended) The method of claim 6, wherein said synthetic peptide has an N-terminal amino acid residue and a C-terminal amino acid residue wherein the N-terminal amino acid residue of the murine epidermal growth factor amino acid residue is chemically modified by the addition of an amino acid capping moiety, the C-terminal amino acid residue of the murine epidermal growth factor amino acid residue is chemically modified by the addition of an amino acid capping moiety, or a murine epidermal growth factor cysteine residue thiol group is chemically modified by the addition of an amino acid capping moiety to the cysteine residue thiol group.

PHIP\390518\1 - 4 -

- 16. (currently amended) The method of claim 15, wherein the murine-epidermal growth factor SEQ ID NO:2 tyrosine residue 5 is substituted by tetrahydroisoquinoline-3-carboxylic acid.
- 17. (currently amended) The method of claim 15 wherein the murine epidermal growth factor SEQ ID NO:2 arginine residue 9 is substituted by Citrulline.
- 18. (previously presented) The method of claim 15 wherein said medicament is for treatment of retinopathy of prematurity.
- 19. (currently amended) A <u>synthetic</u> peptide factor comprising <u>an N-terminal amino acid</u> residue and a C-terminal amino acid residue, and amino acid residues 33 to 42 of murine epidermal growth factor <u>having the sequence of SEQ ID NO:2</u>, wherein
- a) the peptide factor said sequence is modified by at least one first modification and optionally by at least one second modification; and
- b) the <u>synthetic</u> peptide factor <u>binds</u> is capable of binding to laminin receptors, wherein said first modification is selected from the group consisting of: substitution of at least one murine epidermal growth factor <u>SEQ ID NO:2</u> tyrosine amino acid residue <u>5</u> with a tyrosine amino acid residue 9 with an arginine analogue; and

wherein said second modification is selected from the group consisting of: chemical modification of the N-terminal amino acid residue of the murine epidermal growth factor by the addition of an amino acid capping moiety; chemical modification of the C-terminal amino acid residue of the murine epidermal growth factor amino acid residue by the addition of an amino acid capping moiety; chemical modification of a murine epidermal growth factor cysteine residue thiol group by the addition of an amino acid capping moiety to the cysteine residue thiol group; replacement of a peptide bond with a protease-resistant peptide bond isostere, replacement of a glycine residue with $\alpha\alpha$ -dialkyl substituted amino acid; and stabilisation of a helical turn of the peptide using suitable intra chain linkers.

PHIP\390518\1 - 5 -

- 20. (currently amended) A <u>synthetic</u> peptide factor comprising <u>an N-terminal amino acid</u> residue and a C-terminal amino acid residue, and amino acid residues 33 to 42 of murine epidermal growth factor <u>having the sequence of SEQ ID NO:2</u>, wherein
- a) the peptide factor said sequence is modified by at least one first modification and by at least one second modification; and
- b) the <u>synthetic</u> peptide factor <u>binds</u> is capable of binding to laminin receptors, wherein said first modification is selected from the group consisting of: substitution of <u>at least</u> one murine epidermal growth factor <u>SEQ ID NO:2</u> tyrosine amino acid residue <u>5</u> with a tyrosine analogue and substitution of <u>at least one murine epidermal growth factor SEQ ID NO: 2</u> arginine amino acid residue <u>9</u> with an arginine analogue; and wherein said second modification is selected from the group consisting of: chemical modification of the N-terminal <u>amino acid residue</u> of the murine epidermal growth factor by the addition of an amino acid capping moiety; chemical modification of the C-terminal <u>amino acid residue</u> of the murine epidermal growth factor <u>amino acid residue</u> by the addition of an amino acid capping moiety; chemical modification of a murine epidermal growth factor cysteine residue thiol group by the addition of an amino acid capping moiety to the cysteine residue thiol group; replacement of a peptide bond with a protease-resistant peptide bond isostere, replacement of a glycine residue with αα-dialkyl substituted amino acid; and stabilisation of a helical turn of the peptide using suitable intra chain linkers.

21. (canceled)

- 22. (currently amended) The <u>synthetic</u> peptide factor according to claim 19, wherein the <u>murine epidermal growth factor SEQ ID NO:2</u> tyrosine amino acid residue <u>5</u> is substituted by tetrahydroisoquinoline-3-carboxylic acid.
- 23. (currently amended) The <u>synthetic</u> peptide factor according to claim 19 wherein the <u>murine epidermal growth factor SEQ ID NO:2</u> arginine amino acid residue <u>9</u> is substituted by Citrulline.

PHIP\390518\1 - 6 -

- 24. (currently amended) A method of antagonizing a laminin receptor in a patient, the method comprising the steps of:
- a) administering to the patient a medicament comprising a <u>synthetic</u> peptide factor <u>comprising an N-terminal amino acid residue and a C-terminal amino acid residue, and having the sequence of SEQ ID NO:2,</u>

wherein the peptide factor said sequence is modified by at least one first modification and optionally by at least one second modification;

wherein said first modification is selected from the group consisting of: substitution of at least one murine epidermal growth factor SEQ ID NO:2 tyrosine amino acid residue 5 with a tyrosine analogue and substitution of at least one murine epidermal growth factor arginine amino acid residue 9 with an arginine analogue; and

wherein said second modification is selected from the group consisting of: chemical modification of the N-terminal amino acid residue of the murine epidermal growth factor by the addition of an amino acid capping moiety; chemical modification of the C-terminal amino acid residue of the murine epidermal growth factor amino acid residue by the addition of an amino acid capping moiety; chemical modification of a murine epidermal growth factor cysteine residue thiol group by the addition of an amino acid capping moiety to the cysteine residue thiol group; replacement of a peptide bond with a protease-resistant peptide bond isostere, replacement of a glycine residue with $\alpha\alpha$ -dialkyl substituted amino acid; and stabilisation of a helical turn of the peptide using suitable intra chain linkers; and

- b) binding the synthetic peptide factor to the laminin receptor.
- 25. (currently amended) A method of agonizing a laminin receptor in a patient, the method comprising the steps of:
- a) administering to the patient a medicament comprising a <u>synthetic</u> peptide factor <u>comprising an N-terminal amino acid residue and a C-terminal amino acid residue having the sequence of SEQ ID NO:2,</u>

wherein the peptide factor said sequence is modified by at least one first modification and optionally by at least one second modification;

wherein said first modification is selected from the group consisting of: substitution of at least one murine epidermal growth factor SEQ ID NO:2 tyrosine amino acid residue 5 with a

PHIP\390518\1 - 7 -

tyrosine analogue and substitution of at least one murine epidermal growth factor SEQ ID NO: 2 arginine amino acid residue 9 with an arginine analogue; and

wherein said second modification is selected from the group consisting of: chemical modification of the N-terminal of the murine epidermal growth factor by the addition of an amino acid capping moiety; chemical modification of the C-terminal of the murine epidermal growth factor amino acid residue by the addition of an amino acid capping moiety; chemical modification of a murine epidermal growth factor cysteine residue thiol group by the addition of an amino acid capping moiety to the cysteine residue thiol group; replacement of a peptide bond with a protease-resistant peptide bond isostere, replacement of a glycine residue with $\alpha\alpha$ -dialkyl substituted amino acid; and stabilisation of a helical turn of the peptide using suitable intra chain linkers; and

- b) binding the <u>synthetic</u> peptide factor to the laminin receptor.
- 26. (previously presented) The method according to claim 25 wherein said medicament is for treating endothelial cell wounding.
- 27. (previously presented) The method according to claim 25 wherein said medicament is for treatment of retinopathy of prematurity.

PHIP\390518\1 - 8 -